FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 95 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Mom Spots Strange Glow In Daughter’s Eye While Looking At Photo,... April 24, 2019 Cancer in My Community: Caring for the Whole Patient in Brazil December 7, 2023 Growing the Cancer Research Pipeline by Expanding Opportunities August 29, 2024 First targeted treatment approved for advanced prostate cancer on NHS in... October 13, 2021 Load more HOT NEWS Talazoparib Plus Enzalutamide Improves rPFS in First-Line Treatment for Patients with... Metformin May Affect Risk of Breast Cancer in Women with Type... When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... Foodie Fridays: Watermelon Salad
